Impact of Endometrial Compaction on Clinical Pregnancy Rate in Frozen Embryo Transfers

September 1, 2024 updated by: Ain Shams University
To find out if the percentage of endometrial compaction is correlated to clinical pregnancy rate in down regulated frozen embryo transfer cycle. Endometrial compaction is the change in endometrial thickness between the end of the estrogen only phase and the day of embryo transfer. In concept, the compaction of the endometrium after progesterone initiation indicates that the endometrium is responsive to progesterone and could therefore be used as a proxy for endometrial receptivity predictability of FET cycle outcome

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

80

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Infertility patients planning for FET

Description

Inclusion Criteria:

  • Women undergoing down regulated cycles frozen embryo transfer.
  • Women at age group 20-35 years old.
  • Day 5 embryos will be transferred.

Exclusion Criteria:

  • Chromosomal abnormality in either partner (As this could lead to cycle cancellation).
  • Uterine malformation or any intrauterine condition affecting the pregnancy outcomes of FET, such as endometrial polyps, uterine cavity adhesion, history of endometrial tuberculosis, hydrosalpinx with a reflux into uterine cavity (As the might not be candidates for IVF cycle till correction).
  • Recurrent implantation failure, defined as 2 or more previous failed trials (Other confounding factors might of present which could affect the results).
  • Cycles of patients with persistent endometrial thickness <7mm during treatment protocol (Due to cycled cancelation).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
clinical pregnancy rate
Time Frame: 3-4 wks after ET
Clinical pregnancy rate, determined by visualizing a viable embryo within the uterine cavity by ultrasound 3-4 weeks after ET, in patients with endometrial compaction in down regulated FET cycles in comparison to non endometrial compaction.
3-4 wks after ET

Secondary Outcome Measures

Outcome Measure
Time Frame
Percentage of change of endometrial thickness between the end of estrogen administration only phase and the day of embryo transfer.
Time Frame: 3-4 wks after ET
3-4 wks after ET
Chemical pregnancy rates, detected by positive hCG test in the absence of pregnancy findings on TVUS
Time Frame: 3-4 wks after ET
3-4 wks after ET
Number of estrogen administration days
Time Frame: 10 days before ET
10 days before ET

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2024

Primary Completion (Estimated)

September 1, 2024

Study Completion (Estimated)

September 1, 2024

Study Registration Dates

First Submitted

September 1, 2024

First Submitted That Met QC Criteria

September 1, 2024

First Posted (Actual)

September 4, 2024

Study Record Updates

Last Update Posted (Actual)

September 4, 2024

Last Update Submitted That Met QC Criteria

September 1, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • Endometrial Compaction

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on IVF

Subscribe